251 related articles for article (PubMed ID: 12738242)
1. Clinical update: proteasome inhibitors in solid tumors.
Lenz HJ
Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
[TBL] [Abstract][Full Text] [Related]
2. Clinical update: proteasome inhibitors in hematologic malignancies.
Richardson P
Cancer Treat Rev; 2003 May; 29 Suppl 1():33-9. PubMed ID: 12738241
[TBL] [Abstract][Full Text] [Related]
3. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
4. Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Cusack JC
Cancer Treat Rev; 2003 May; 29 Suppl 1():21-31. PubMed ID: 12738240
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors as new anticancer drugs.
Adams J
Curr Opin Oncol; 2002 Nov; 14(6):628-34. PubMed ID: 12409653
[TBL] [Abstract][Full Text] [Related]
6. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
[TBL] [Abstract][Full Text] [Related]
7. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
8. The proteasome: structure, function, and role in the cell.
Adams J
Cancer Treat Rev; 2003 May; 29 Suppl 1():3-9. PubMed ID: 12738238
[TBL] [Abstract][Full Text] [Related]
9. The role of proteasome inhibitors in solid tumors.
Park DJ; Lenz HJ
Ann Med; 2004; 36(4):296-303. PubMed ID: 15224656
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition: a novel approach to cancer therapy.
Adams J
Trends Mol Med; 2002; 8(4 Suppl):S49-54. PubMed ID: 11927288
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
[TBL] [Abstract][Full Text] [Related]
12. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.
Ling YH; Liebes L; Zou Y; Perez-Soler R
J Biol Chem; 2003 Sep; 278(36):33714-23. PubMed ID: 12821677
[TBL] [Abstract][Full Text] [Related]
14. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
[TBL] [Abstract][Full Text] [Related]
15. [Proteasome inhibitor].
Yamamura M; Hirai T; Yamaguchi Y
Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Kamat AM; Karashima T; Davis DW; Lashinger L; Bar-Eli M; Millikan R; Shen Y; Dinney CP; McConkey DJ
Mol Cancer Ther; 2004 Mar; 3(3):279-90. PubMed ID: 15026548
[TBL] [Abstract][Full Text] [Related]
17. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
18. [Proteasome inhibitors].
Hatake K; Mishima Y; Terui Y
Gan To Kagaku Ryoho; 2004 Jul; 31(7):999-1002. PubMed ID: 15272575
[TBL] [Abstract][Full Text] [Related]
19. Targeting the ubiquitin-proteasome pathway in breast cancer.
Cardoso F; Ross JS; Picart MJ; Sotiriou C; Durbecq V
Clin Breast Cancer; 2004 Jun; 5(2):148-57. PubMed ID: 15245620
[TBL] [Abstract][Full Text] [Related]
20. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]